par Denkert, Carsten;Von Minckwitz, Gunter;Brase, Jan JC;Sinn, Bruno BV;Gade, Stephan;Kronenwett, Ralf;Pfitzner, Berit BM;Salat, Christoph;Loi, Sherene 
;Schmitt, Wilhelm;Schem, C.;Fisch, Karin;Darb-Esfahani, Silvia;Mehta, Keyur;Sotiriou, Christos ;Wienert, Stephan;Klare, Peter;Andre, Fabrice;Klauschen, Frederick;Blohmer, Jens-Uwe J;Krappmann, Kristin;Schmidt, Marcus;Tesch, Hans;Kümmel, Sherko;Sinn, Peter;Jackisch, Christian;Dietel, Manfred;Reimer, T;Untch, Michael;Loibl, Sibylle
Référence Journal of clinical oncology
Publication Publié, 2014-12
;Schmitt, Wilhelm;Schem, C.;Fisch, Karin;Darb-Esfahani, Silvia;Mehta, Keyur;Sotiriou, Christos ;Wienert, Stephan;Klare, Peter;Andre, Fabrice;Klauschen, Frederick;Blohmer, Jens-Uwe J;Krappmann, Kristin;Schmidt, Marcus;Tesch, Hans;Kümmel, Sherko;Sinn, Peter;Jackisch, Christian;Dietel, Manfred;Reimer, T;Untch, Michael;Loibl, SibylleRéférence Journal of clinical oncology
Publication Publié, 2014-12
Article révisé par les pairs
| Résumé : | Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. |
